SOUTH SAN FRANCISCO, Calif., March 23, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a
clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced that Keith Orford,
M.D., Ph.D, the company’s Senior Vice President of Clinical Development, will present at the Needham & Company 17th
Annual Healthcare Conference at 2:00 p.m. ET on Wednesday, March 28, 2018 in New York City. The presentation will be webcast live
and available for replay for up to 30 days at www.calithera.com in the Investor Relations section.
About Calithera
Calithera is a clinical-stage biopharmaceutical company focused on fighting cancer by discovering, developing, and
commercializing novel small molecule drugs that target tumor and immune cell metabolism. Calithera is headquartered in South San
Francisco, California. For more information about Calithera, please visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate,"
"estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events,
conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to
the safety, tolerability and efficacy of CB-839, the overall advancement of CB-839 in clinical trials, the unmet need in the
treatment of patients with advanced disease, and Calithera’s plans to continue development of CB-839 in combination with everolimus
for the treatment of clear cell renal cell carcinoma. Because such statements are subject to risks and uncertainties, actual
results may differ materially from those expressed or implied by such forward-looking statements. The product candidates that
Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines
or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed
in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The
failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock
price. Additional information concerning these and other risk factors affecting Calithera's business can be found in
Calithera's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, and other periodic filings
with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future
performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update
these forward-looking statements to reflect future events or circumstances.
SOURCE: Calithera Biosciences, Incorporated
CONTACT:
Jennifer McNealey
ir@Calithera.com
650-870-1071
